- Condition: HIV Dementia
Interventions: Drug: Long acting methylphenidate; Drug: Long acting methylphenidate; Drug: Matched placebo
Sponsors: University of California, Los Angeles; University of California, Los Angeles
Recruiting - verified May 2012 - Condition: Attention-deficit/Hyperactivity Disorder
Interventions: Drug: Lisdexamfetamine dimesylate; Drug: Methylphenidate Hydrochloride; Drug: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2012 - Condition: Attention-deficit/Hyperactivity Disorder
Interventions: Drug: Lisdexamfetamine dimesylate; Drug: Methylphenidate Hydrochloride; Drug: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2012 - Conditions: Attention Deficit Hyperactivity Disorder (ADHD); Executive Function Deficits (EFD)
Interventions: Drug: Placebo; Drug: Memantine Hydrochloride; Drug: OROS-Methylphenidate
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; American Professional Society of ADHD and Related Disorders
Not yet recruiting - verified April 2012 - Conditions: Posttraumatic Stress Disorder; Traumatic Brain Injury
Interventions: Drug: Methylphenidate Hydrochloride 20 mg; Drug: Placebo Capsule; Drug: Galantamine 12 mg
Sponsors: INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium; INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium; U.S. Army Medical Research and Materiel Command
Recruiting - verified January 2012 - Condition: Prostate Cancer
Interventions: Other: Placebo; Drug: Methylphenidate; Behavioral: Counseling Sessions; Other: Sham Exercise; Other: Standardized Exercise Intervention Program; Other: Cognitive Behavioral Therapy (CBT)
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; American Cancer Society
Recruiting - verified April 2012 - Conditions: Attention Deficit Hyperactivity Disorder (ADHD); Deficient Emotional Self-Regulation (DESR)
Interventions: Drug: OROS-Methylphenidate; Drug: Omega-3 Fatty Acids
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified February 2012 - Condition: Cocaine Dependence
Intervention: Drug: Buspirone
Sponsors: The University of Texas Health Science Center, Houston; The University of Texas Health Science Center, Houston
Recruiting - verified March 2012 - Condition: Attention Deficit/Hyperactivity Disorder
Interventions: Drug: Placebo; Drug: RIT124D; Drug: RIT124D; Drug: RIT124D
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Pervasive Development Disorders
Interventions: Drug: extended-release guanfacine; Other: placebo
Sponsors: Yale University; Yale University; Massachusetts General Hospital; Seattle Children's Hospital; University of California, Los Angeles; National Institute of Mental Health (NIMH)
Recruiting - verified May 2012 - Condition: ADHD
Intervention:
Sponsors: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Recruiting - verified May 2012 - Conditions: Attention Deficit Hyperactivity Disorder; Reading Difficulty or Disability
Interventions: Drug: Methylphenidate; Behavioral: Intensive reading instruction; Behavioral: Parent Training; Drug: Mixed Salt Amphetamine; Drug: Atomoxetine; Drug: Guanfacine
Sponsors: The University of Texas Health Science Center, Houston; The University of Texas Health Science Center, Houston; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified February 2012 - Conditions: Smoking; ADHD
Intervention:
Sponsors: Duke University; Duke University; National Institute on Drug Abuse (NIDA)
Recruiting - verified February 2012 - Conditions: ADHD; Growth
Interventions: Behavioral: behavioral therapy; Drug: 12 hour methylphenidate product; Behavioral: increased monitoring of growth; Drug: drug holiday; Dietary Supplement: caloric supplement
Sponsors: Florida International University; Florida International University
Recruiting - verified March 2012 - Condition: Attention-Deficit/Hyperactivity Disorder
Interventions: Drug: Lisdexamfetamine Dimesylate; Drug: Atomoxetine Hydrochloride
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified March 2012 - Condition: Attention Deficit Hyperactivity Disorder
Intervention: Drug: Osmotic Release Methylphenidate
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; ElMindA Ltd
Recruiting - verified October 2011 - Condition: Methamphetamine Dependence
Interventions: Drug: methylphenidate; Drug: Methylphenidate
Sponsors: University of California, Los Angeles; University of California, Los Angeles
Recruiting - verified January 2010 - Condition: Drug Abuse
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute on Drug Abuse (NIDA)
Recruiting - verified March 2012 - Condition: Attention Deficit/Hyperactivity Disorder
Interventions: Drug: Short Acting Methylphenidate; Drug: Long Acting Methylphenidate
Sponsors: BRC Operations Pty. Ltd.; BRC Operations Pty. Ltd.
Recruiting - verified January 2012 - Conditions: Mood Disorder; Mental Disorder Diagnosed in Childhood; Attention Deficit and Disruptive Behavior Disorder; Attention Deficit Hyperactivity Disorder
Interventions: Drug: Citalopram; Drug: Methylphenidate
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Mental Health (NIMH)
Recruiting - verified July 2011 - Condition: Stroke
Interventions: Drug: Sinemet, ritalin, amphetamine, and placebo; Device: Transcranial magnetic stimulation (TMS); Other: Combined drug treatment and TMS
Sponsors: Emory University; Emory University; National Institutes of Health (NIH); National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified April 2012 - Condition: Eating Disorders
Interventions: Radiation: Positron Emission Tomography (PET) using [11C]raclopride; Drug: Methylphenidate; Procedure: Magnetic Resonance Imaging (MRI) scan
Sponsors: National Institute of Mental Health (NIMH); National Institute of Mental Health (NIMH)
Recruiting - verified November 2011 - Condition: Brain Injury
Interventions: Drug: Methylphenidate; Behavioral: Memory and Attention Training; Other: Placebo as both treatments
Sponsors: Dartmouth-Hitchcock Medical Center; Dartmouth-Hitchcock Medical Center; National Institutes of Health (NIH)
Recruiting - verified October 2011 - Conditions: Autonomic Failure; Orthostatic Hypotension
Interventions: Drug: Atomoxetine; Drug: Acarbose; Drug: Pyridostigmine Bromide; Drug: Yohimbine; Drug: Midodrine HCl; Drug: placebo; Drug: Modafinil; Drug: Octreotide; Other: water intake; Drug: Diphenhydramine Hydrochloride; Drug: Ranitidine HCL; Drug: Tranylcypromine; Drug: Ergotamine/ Caffeine; Drug: Celecoxib; Drug: Pseudoephedrine; Drug: Methylphenidate; Drug: Indomethacin; Drug: Ibuprofen; Drug: Oxymetazoline 0.05% nasal solution; Dietary Supplement: Bovril; Drug: Acetazolamide; Drug: Rivastigmine tartrate; Drug: Carbidopa/levodopa; Device: abdominal binder; Device: abdominal binder (sham)
Sponsors: Vanderbilt University; Vanderbilt University
Recruiting - verified May 2012
 |
Concerta Clinical Trials |
